On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK), the first-in-class EZH2 inhibitor. The...
FDA
In February 2022, the Food and Drug Administration (FDA) approved nivolumab with platinum-doublet chemotherapy for adult patients with resectable non-small...
In February 2022, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel for Janssen Biotech for the treatment of adult...
Several indications and molecules were approved in December by FDA including the following: Abatacept for the prophylaxis of acute graft...
Several indications and molecules were approved in November by FDA including the following: 1- Pembrolizumab for the adjuvant treatment of...
Several indications and molecules were approved in October by FDA including the following: 1- Brexucabtagene autoleucel for adult patients with...
Several indications and molecules were approved in August by FDA including the following: 1- Lenvatinib plus pembrolizumab for first-line treatment...
Several indications and molecules were approved in July by FDA including the following: Asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component...
The Food and Drug Administration(FDA) approved avapritinib for adult patients with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis...
The Food and Drug Administration (FDA) has given bluebird bio the green light to resume its clinical trials of gene therapy, LentiGlobin....
